FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial

The NIVACOR trial is a phase II study assessing the efficacy and safety of nivolumab in combination with FOLFOXIRI/bevacizumab in first-line setting in patients affected by metastatic colorectal cancer (mCRC) RAS/BRAF mutated. We report safety run-in results in the first 10 patients enrolled. Patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Damato, Angela, Bergamo, Francesca, Antonuzzo, Lorenzo, Nasti, Guglielmo, Iachetta, Francesco, Romagnani, Alessandra, Gervasi, Erika, Larocca, Mario, Pinto, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712943/
https://www.ncbi.nlm.nih.gov/pubmed/34970487
http://dx.doi.org/10.3389/fonc.2021.766500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712943/
https://www.ncbi.nlm.nih.gov/pubmed/34970487
http://dx.doi.org/10.3389/fonc.2021.766500

Ejemplares similares